Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2017

17.12.2016 | Original Article

Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study

verfasst von: Peter Brinks, Koen Van Gils, Ellen Kranenborg, Jules Lavalaye, Dennis Dieckens, Jan B. A. Habraken

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Radionuclide therapy using I-131 is commonly used for the treatment of benign thyroid diseases. The therapeutic dose to be administered is calculated based on the type of disease, the volume of the thyroid, and the measured uptake percentage. This methodology assumes a similar biological half-life of iodine, whereas in reality a large variation in biological half-life is observed. More knowledge about the actual biological half-life of iodine for individual patients will improve the quantification of the delivered radiation dose during radioiodine therapy and could aid the evaluation of the success of the therapy. In this feasibility study we used a novel measurement device [Collar Therapy Indicator (CoTI)] to measure the uptake curve of patients undergoing I-131 radioiodine therapy. The CoTI device is a light-weight wearable device that contains two independent gamma radiation detectors that are placed in a collar. By comparing results of thyroid uptake measurements with results obtained with a gamma camera, the precision of the system is demonstrated. Additionally, for three patients the uptake curve is measured during 48 h of admission in the hospital. The presented results demonstrate the feasibility of the new measurement device to measure the uptake curve during radioiodine therapy.
Literatur
1.
Zurück zum Zitat Czepczynski R. Nuclear medicine in the diagnosis of benign thyroid diseases. Nucl Med Rev Cent East Eur. 2012;15:113–9.PubMed Czepczynski R. Nuclear medicine in the diagnosis of benign thyroid diseases. Nucl Med Rev Cent East Eur. 2012;15:113–9.PubMed
2.
Zurück zum Zitat Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med. 1996;26:155–64.CrossRefPubMed Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med. 1996;26:155–64.CrossRefPubMed
3.
Zurück zum Zitat Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31:201–5.CrossRefPubMed Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31:201–5.CrossRefPubMed
4.
Zurück zum Zitat Willegaignon J, Sapienza MT, Coura Filho GB, Traino AC, Buchpiguel CA. Determining thyroid (131)I effective half-life for the treatment planning of Graves’ disease. Med Phys. 2013;40:022502.CrossRefPubMed Willegaignon J, Sapienza MT, Coura Filho GB, Traino AC, Buchpiguel CA. Determining thyroid (131)I effective half-life for the treatment planning of Graves’ disease. Med Phys. 2013;40:022502.CrossRefPubMed
5.
Zurück zum Zitat Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med. 1996;37:228–32.PubMed Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med. 1996;37:228–32.PubMed
6.
Zurück zum Zitat Flower MA, Schlesinger T, Hinton PJ, Adam I, Masoomi AM, Elbelli MA, et al. Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol. 1989;15:345–57.CrossRefPubMed Flower MA, Schlesinger T, Hinton PJ, Adam I, Masoomi AM, Elbelli MA, et al. Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol. 1989;15:345–57.CrossRefPubMed
7.
Zurück zum Zitat Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.CrossRefPubMed Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.CrossRefPubMed
8.
Zurück zum Zitat Hanscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40:1126–34.CrossRefPubMed Hanscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40:1126–34.CrossRefPubMed
9.
Zurück zum Zitat Benjamin RS, Amro A, El-Desouki MI. Measurement of iodine-123 thyroid uptake using a gamma camera with LEAP collimator. J Nucl Med Technol. 1999;27:215–9.PubMed Benjamin RS, Amro A, El-Desouki MI. Measurement of iodine-123 thyroid uptake using a gamma camera with LEAP collimator. J Nucl Med Technol. 1999;27:215–9.PubMed
10.
Zurück zum Zitat Balon HR, Silberstein EB, Meier DA, Charkes ND, Royal HD, Sarkar SD, Donohoe KJ. Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement. Society of Nuclear Medicine Procedure Guidelines 2006. Balon HR, Silberstein EB, Meier DA, Charkes ND, Royal HD, Sarkar SD, Donohoe KJ. Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement. Society of Nuclear Medicine Procedure Guidelines 2006.
Metadaten
Titel
Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study
verfasst von
Peter Brinks
Koen Van Gils
Ellen Kranenborg
Jules Lavalaye
Dennis Dieckens
Jan B. A. Habraken
Publikationsdatum
17.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3595-y

Weitere Artikel der Ausgabe 6/2017

European Journal of Nuclear Medicine and Molecular Imaging 6/2017 Zur Ausgabe